A retrospective observational study in adult patients with type 2 diabetes who switched from using insulin glargine 100 Units/mL to Toujeo (Insulin glargine (Insulin U300)) or insulin degludec
Phase of Trial: Phase IV
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Insulin glargine (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DELIVER D
- 12 Dec 2017 Results from LIGHTNING and Deliver D studies published in a Sanofi media release.
- 05 Dec 2017 New trial record
- 30 Nov 2017 According to a Sanofi media release, results from the study were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.